Critical Appraisal of International Guidelines for the Management of Diabetic Neuropathy: Is There Global Agreement in the Internet Era?

Table 7

Results of the assessment of the symptom management recommendations using the AGREE II instrument (domain scores in %).

	D1	D2	D3	D4	D5	D6	Ave	Overall assessment
ADA	55.6	50.0	31.3	61.1	0.0	50.0	41.3	M
UMHS	50.0	33.3	25.0	44.4	4.2	50.0	34.5	M
AACE	50.0	33.3	31.3	44.4	0.0	16.7	29.3	M
PNICE	100.0	61.1	75.0	100.0	37.5	50.0	70.6	SR
IDF	50.0	22.2	39.6	88.9	54.2	33.3	48.0	M
NZGG	77.8	55.6	33.3	94.4	45.8	50.0	59.5	M
AAN	55.6	22.2	68.8	88.9	8.3	50.0	49.0	M
TEPDN	33.3	27.8	6.3	50.0	0.0	25.0	23.7	N
SFD	0.0	27.8	14.6	38.9	25.0	25.0	21.9	N
SIGN	88.9	88.9	81.3	100.0	95.8	33.3	81.4	SR
EFNS	33.3	38.9	35.4	61.1	12.5	25.0	34.4	M
NICE	72.2	77.8	87.5	100.0	16.7	58.3	68.8	SR
SADA	55.6	0.0	4.2	44.4	4.2	0.0	18.1	N
Ave	55.6	41.5	41.0	70.5	23.4	35.9

Ave indicates average. SR indicates being strongly recommended for use in clinical practice. M indicates being recommended for use in clinical practice with some modifications. N indicates being not recommended for use in clinical practice.
D1 (domain 1) indicates scope and purpose; D2 (domain 2) indicates stakeholder involvement; D3 (domain 3) indicates rigor of development; D4 (domain 4) indicates clarity of presentation; D5 (domain 5) indicates applicability; D6 (domain 6) indicates editorial independence.